Enhanced Sensitivity to Gefitinib after Radiation in Non-Small Cell Lung Cancer Cells.
10.4046/trd.2011.71.4.259
- Author:
Yun Jung CHOI
1
;
Jin Kyung RHO
;
Dae Hyun BACK
;
Hye Ryoun KIM
;
Jae Cheol LEE
;
Cheol Hyeon KIM
Author Information
1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
gefitinib;
Radiation;
Carcinoma, Non-Small-Cell Lung
- MeSH:
Apoptosis;
Asian Continental Ancestry Group;
Blotting, Western;
Carcinoma, Non-Small-Cell Lung;
Caspase 3;
Cell Line;
Cell Proliferation;
Cell Survival;
Flow Cytometry;
Humans;
Parents;
Protein-Tyrosine Kinases;
Quinazolines;
Radiation, Ionizing;
Receptor, Epidermal Growth Factor;
Erlotinib Hydrochloride
- From:Tuberculosis and Respiratory Diseases
2011;71(4):259-265
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib, are effective therapies for non-small cell lung cancer (NSCLC) patients whose tumors harbor somatic mutations in EGFR. The mutations are, however, only found in about 30% of Asian NSCLC patients and all patients ultimately develop resistance to these agents. Ionizing radiation has been shown to induce autophosphorylation of EGFR and activate its downstream signaling pathways. In the present study, we have tested whether the effect of gefitinib treatment can be enhanced after ionizing radiation. METHODS: We compared the PC-9 and A549 cell line with its radiation-resistant derivatives after gefitinib treatment with cell proliferation and apoptosis assay. We also analyzed the effect of gefitinib after ionizing radiation in PC-9, A549, and NCI-H460 cells. Cell proliferation was determined by MTT assay and induction of apoptosis was evaluated by flow cytometry. Caspase 3 activation and PARP cleavage were evaluated by western blot analysis. RESULTS: PC-9 cells having mutated EGFR and their radiation-resistant cells showed no significant difference in cell viability. However, radiation-resistant A549 cells were more sensitive to gefitinib than were their parental cells. This was attributable to an increased induction of apoptosis. Gefitinib-induced apoptosis increased significantly after radiation in cells with wild type EGFR including A549 and NCI-H460, but not in PC-9 cells with mutated EGFR. Caspase 3 activation and PARP cleavage accompanied these findings. CONCLUSION: The data suggest that gefitinib-induced apoptosis could increase after radiation in cells with wild type EGFR, but not in cells with mutated EGFR.
